Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model
- 679 Downloads
This article describes the adaptation of a model estimating the burden of postmenopausal osteoporosis (PMO) to the UK.
The purpose of this study was to estimate the present and future epidemiology of PMO in the UK.
For each year of the study, the ‘incident cohort’ (women experiencing a first osteoporotic fracture) was identified and run through a Markov model using 1-year cycles until 2020. Health states were based on the number of fractures and death. Fracture by site was tracked for each health state. Transition probabilities reflected fracture site-specific risk of death and subsequent fractures.
Assuming that the rate of incident fractures by age is constant over time, the model estimated the total number of PMO fractures at 224,219 in 2010, including 51,927 hip and 30,994 clinical vertebral fractures. These estimates were predicted to increase by 17.2%, 16.6% and 17.9%, respectively, by 2020. The number of postmenopausal women living with osteoporosis was predicted to increase from 1.8 million in 2010 to 2.1 million in 2020 (+16.5%). A sensitivity analysis demonstrated that the estimated number of fractures is most sensitive to the assumption made on the trends in the rate of incidence.
The PMO disease model, first developed for Sweden, was adapted to the UK. Due to demographic changes, the burden of osteoporosis is expected to increase by almost a fifth by 2020. Due to the lack of country-specific data, these results rely on several assumptions regarding the incidence of non-hip fractures, trends in BMD and rate of incidence over time.
KeywordsBone mineral density Epidemiology Fracture Osteoporosis T score UK
This study was supported by the International Osteoporosis Foundation and funded by Amgen (Europe) GmbH. The authors thank Dr. Matthew Gitlin and Sean Robbins from Amgen (Europe) GmbH for their involvement in this project, and Professor Alistair McGuire from the London School of Economics for his advice on the model development. Funds were provided by Amgen (Europe) GmbH and GlaxoSmithKline to Bioscript Stirling for minor editing and styling support.
Conflicts of interest
J.A. Kanis, E. McCloskey, and C. Cooper have no conflicts of interest. J. Compston has received grant funding from Osteotronix and Nycomed; received speaking and/or advisory fees from Novartis, Amgen, Servier, GSK, Gilead, Procter & Gamble/Sanofi Aventis, Eli Lilly, Merck Sharp & Dohme, Medtronic and Warner-Chilcott; and has provided consultancy to Novartis and Amgen. The work undertaken by A. Gauthier, Y. Jiang, M. Martin and F. Borgstrom on the analysis and model development was done under contract to Amgen.
- 1.[No authors listed] (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646–650Google Scholar
- 2.World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series no. 843. World Health Organization, Geneva, pp 1–129Google Scholar
- 3.Kanis JA; on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UKGoogle Scholar
- 5.Department of Health and Human Services (2004) Bone Health and Osteoporosis: A Report of the Surgeon General. Department of Health and Human Services, WashingtonGoogle Scholar
- 20.Office for National Statistics, General Register Office for Scotland, and Northern Ireland Statistics and Research Agency. http://www.statistics.gov.uk. Accessed 26 October 2007
- 21.Government Actuary’s Department, Projections database: 2006-based principal projections. http://www.gad.gov.uk/Demography%20Data/Population/index.aspx?y=2006&v=Principal. Accessed 20 October 2010
- 24.NICE (National Institute for Clinical Excellence) (2008) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. London. www.nice.org.uk. Accessed 16 November 2010
- 28.Balasegaram S, Majeed A, Fitz-Clarence H (2002) Trends in hospital admissions for fractures of the hip and femur in England, 1989–1990 to 1997–1998. J Public Health Med 23:11–17Google Scholar
- 35.NICE (2008) National Institute for Clinical Excellence (NICE) technology appraisal guidance 160. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. http://www.nice.org.uk/TA160. Accessed 17 November 2010
- 36.Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A; National Osteoporosis Guideline Group Case finding for the management of osteoporosis with FRAX®—Assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395–1408. Erratum Osteoporos Int 2009;20:499–502Google Scholar
- 38.World Health Organization (2004) Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2002. The World Health Report 2004: changing history. World Health Organization, Geneva, pp 126–131Google Scholar